承慶堂品牌怎么样 申请店铺

我要投票 承慶堂在医疗器械行业中的票数:343 更新时间:2025-06-30
承慶堂是哪个国家的品牌?「承慶堂」是 安徽承庆堂国药股份有限公司 旗下著名品牌。该品牌发源于安徽省亳州市,由创始人李整风在2012-01-17期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力承慶堂品牌出海!将品牌入驻外推网,定制承慶堂品牌推广信息,可以显著提高承慶堂产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

承慶堂怎么样

安徽承庆堂国药股份有限公司(原亳州正丰医药有限责任公司)是于2001年投资建设的集医疗器械生产与销售一体化公司,是一家集医疗器械的技术研发、技术咨询为产业核心,采用国际OEM模式,以掌控知识产权为入手、以医药科研为主的企业,主打“承庆堂”骨病系列外用贴剂产品,以疗效显著、品质稳定深得广大骨科医院及消费者的认可和好评。公司在医药行业经过短短几年的发展历程,依靠自身产品的绝对疗效已形成了骨病系列外用贴剂的知名品牌。“品质决定品牌”,创造骨病系列外用贴剂的医药品牌是正丰医药人孜孜不倦和执着追求的目标。

公司拥有一支团结、创新、奋进的技术研发队伍,在公司全体员工的共同努力下,企业坚持走专业化道路,形成了“材料来源基地化,检测手段科学化,制作工艺规范化,贴剂质量标准化,设计包装规格化”的“五化”管理模式,产品“选料上乘,工艺考究,疗效显著”。提升了“承庆堂”品牌的知名度和美誉度。始终坚持靠诚信打造自身品牌、靠质量占领市场先机、靠服务赢得行业机遇、靠管理推动企业发展的理念,在严峻的医药行业形势下,注重发挥自身优势,做大做强主营业务,我们坚信“一生只做一件事”,在同行业内取得了骄人的业绩,公司在发展过程中,得到了各级领导和相关职能管理部门的正确指引和极大的关怀,在广大医药流通企业和商业客户的支持下,在全国药业行业中,凭借自身实力和产品品质,铸就了企业在医药行业及广大骨科医院的巩固地位。目前,公司已与国内多家骨科医院和众多客户建立了紧密、稳固的合作关系,形成了强大的销售网络和品牌优势。公司也一直专注于现代企业制度的建设,目前已经在企业的产权结构、运营模式、管理制度、业务流程上达到了一定水平,并形成了自己的特色。

公司自2007年就尝试运作终端销售模式,即在有条件的骨科医院设立精品药房,截至目前已在国内多家骨科医院建立了上百家精品药房,此模式的成功运作,有利于实现名企、名院、名医、名品的优化组合,扩大医疗机构的服务范围,为患者提供疗效显著、价格合理的诚信医疗服务。我们诚邀各大骨科医院垂询来访,共筑合作平台,实现医药携手共赢发展。

在如今医药行业新的竞争和挑战中,我们将拥有更加广阔的医药市场。“海内存知己,天涯若比邻”,公司愿与全国各大骨科医院、连锁药房及各界的朋友真诚合作、共创辉煌!



Anhui chengqingtang State Pharmaceutical Co., Ltd. (formerly Bozhou Zhengfeng Pharmaceutical Co., Ltd.) is an integrated production and sales company of medical devices invested and constructed in 2001. It is an enterprise that focuses on technical research and development and technical consultation of medical devices, adopts the international OEM mode, controls intellectual property rights and focuses on medical research, and focuses on "chengqingtang" osteopathy A series of external patch products, with remarkable curative effect and stable quality, have won the recognition and praise of orthopedic hospitals and consumers. After just a few years of development in the pharmaceutical industry, relying on the absolute efficacy of its own products, the company has formed a well-known brand of bone disease series external patches. "Quality determines the brand" and creating a brand of external use of orthopedic patches is the goal of Zhengfeng pharmaceutical people. The company has a united, innovative and progressive technology research and development team. With the joint efforts of all employees, the company adheres to the path of specialization, forming a "five chemical" management mode of "base of material sources, scientific detection means, standardized production process, standardized paste quality, standardized design and packaging". The product "selects the best materials, exquisite technology, and curative effect" Remarkable. It has improved the popularity and reputation of chengqingtang brand. We always adhere to the concept of building our own brand by integrity, seizing the market opportunity by quality, winning industry opportunities by service, and promoting enterprise development by management. Under the severe situation of the pharmaceutical industry, we pay attention to giving full play to our own advantages and making our main business bigger and stronger. We firmly believe that "only one thing in life" has made remarkable achievements in the same industry. In the process of development, the company has obtained With the correct guidance and great care of leaders at all levels and relevant functional management departments, supported by the majority of pharmaceutical circulation enterprises and commercial customers, and with its own strength and product quality in the national pharmaceutical industry, the company has established a firm position in the pharmaceutical industry and the majority of orthopedic hospitals. At present, the company has established close and stable cooperative relations with many orthopedic hospitals and customers in China, forming a strong sales network and brand advantages. The company has also been focusing on the construction of modern enterprise system. At present, it has reached a certain level in the property right structure, operation mode, management system and business process of the enterprise, and has formed its own characteristics. Since 2007, the company has tried to operate terminal sales mode, that is, to set up boutique pharmacies in conditional orthopedic hospitals. Up to now, hundreds of boutique pharmacies have been set up in many orthopedic hospitals in China. The successful operation of this mode is conducive to the realization of the optimized combination of famous enterprises, famous hospitals, famous doctors and famous products, the expansion of the service scope of medical institutions, and the provision of significant curative effect and reasonable price for patients The integrity of medical services. We sincerely invite all orthopedic hospitals to visit us and build a cooperation platform to achieve win-win development of medicine. In today's new competition and challenges in the pharmaceutical industry, we will have a broader pharmaceutical market. "Friends in the sea, the end of the world is like a neighbor", the company is willing to sincerely cooperate with all major orthopedic hospitals, chain pharmacies and friends from all walks of life to create brilliant!

本文链接: https://brand.waitui.com/8a4ae9536.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

华为近期一项语音助手相关专利公布

36氪获悉,6月29日,余承东透露华为Pura80系列将在8月上线“AI超级智能体”。爱企查App显示,华为技术有限公司已申请注册多枚“小艺小艺”商标,国际分类涉及科学仪器、广告销售、餐饮住宿等,目前上述商标多数已注册成功。此外,2025年5月,该公司一项名为“语音助手交互的方法和电子设备”的发明专利公布,该专利所述的电子设备可以根据自身的设备姿态和设备动作来确定是否唤醒语音助手,其中该设备姿态可以是结合电子设备的多种传感器的测量数据确定的。

39分钟前

港车北上政策两周年,出入境车辆超285万辆次

“港车北上”政策自2023年7月1日落地实施以来,带动粤港澳大湾区互联互通与融合发展进一步提速。据港珠澳大桥边检站数据显示,截至今年6月30日,完成“港车北上”边检备案车辆已超过10.8万辆次、备案司机超12.9万人次,经该边检站查验的出入境“港车北上”数量已超过285万辆次。(大湾区之声)

39分钟前

雷军:小米YU7锁单远超预期,将于7月2日晚8点做一场直播

36氪获悉,小米集团董事长雷军发文称,小米YU7发布以来,媒体和用户朋友们在试驾后给出了很多好评,锁单也远超预期,将于7月2日晚8点做一场直播,集中回答大家关心的一些问题。

39分钟前

半日主力资金加仓国防军工股,抛售非银金融股

主力资金早间净流入国防军工、传媒、电子等板块,净流出非银金融、银行、有色金属等板块。具体到个股来看,成飞集成、大东南、东信和平获净流入10.73亿元、8.88亿元、8.47亿元。净流出方面,平安银行、比亚迪、台基股份遭抛售3.13亿元、2.72亿元、2.62亿元。(第一财经)

39分钟前

英诺赛科最大基石投资者承诺延长限售

6月30日,氮化镓功率半导体企业英诺赛科发布公告,其最大基石投资者意法半导体(STM)原禁售期于6月29日到期后,已书面承诺未来12个月内不减持任何股份。意法半导体目前持有英诺赛科12592100股H股,占已发行H股总数约2.56%,占当前可流通H股总数约27%。这一承诺彰显了对英诺赛科长期发展的坚定信心。此外,近期,财通证券、招银国际、中信里昂、广发证券、华创证券、国金证券等多家券商发布研报,一致给予积极评级。

39分钟前

本页详细列出关于承慶堂的品牌信息,含品牌所属公司介绍,承慶堂所处行业的品牌地位及优势。
咨询